Artistas sobre outras obras

Este número da Revista Estúdio assinala a crescente maturação de um espaço de comunicação algo alternativo, onde artistas falam de artistas, dão a conhecer obras menos conhecidas, e ocupam uma área de curadoria expontânea e paralela aos centros do arte world. Dá-se a palavra aos próprios criadores, e há seis anos que o seu olhar vem enriquecendo um património crescente, com especiais ligações aos países onde se fala as línguas ibéricas. A presença de obras de Portugal, Espanha, Brasil, Angola, Argentina, Perú, Venezuela, Bolívia e muitos outros países tornou-se habitual, fazendo da Estúdio uma instância da semiosfera (Lotman). Mais do que a presença, é a dimensão do conhecimento transmitido, a que se segue, naturalmente, o estabelecimento de novas teias de referência entre os artistas destes países: há novos grupos, novas cumplicidades, novas realizações dentro deste Estúdio, que completa seis anos de publicação persistente. A Revista Estúdio é também mais uma via disponível para o exercício da interpretação, através de descodificações mais informadas, mais negociadas, dos textos artísticos, pois são efectuadas por outros artistas. Reuniram-se nesta edição 24 artigos originais, mantendo a sua linha editorial inicial. O projecto mantém a sua componente de resistência, de plataforma de conhecimento para os pares, não abdicando também da validação externa, ou seja, do uso de protocolos de produção e transmissão de conhecimento. Falamos pois das normas de redação, de referenciação, de estruturação de textos e de articulação de argumentos, visuais ou verbais. Estabelece-se neste volume uma articulação entre cinema, vídeo, redes, escultura, instalação, fotografia, performance, banda desenhada, pintura, cerâmica, poesia concreta, livros de artista, sendo este conjunto não exaustivo testemunha do grau de hibridação que hoje o discurso artístico convoca. Apanhando-lhe o pulso, a Estúdio acompanha a arte desde os seus produtores, dos seus procedimentos, dos seus recursos, dos seus resultados. A Estúdio permite visitar muitos estúdios.info:eu-repo/semantics/publishedVersio

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016) : part two

Background The immunological escape of tumors represents one of the main ob- stacles to the treatment of malignancies. The blockade of PD-1 or CTLA-4 receptors represented a milestone in the history of immunotherapy. However, immune checkpoint inhibitors seem to be effective in specific cohorts of patients. It has been proposed that their efficacy relies on the presence of an immunological response. Thus, we hypothesized that disruption of the PD-L1/PD-1 axis would synergize with our oncolytic vaccine platform PeptiCRAd. Methods We used murine B16OVA in vivo tumor models and flow cytometry analysis to investigate the immunological background. Results First, we found that high-burden B16OVA tumors were refractory to combination immunotherapy. However, with a more aggressive schedule, tumors with a lower burden were more susceptible to the combination of PeptiCRAd and PD-L1 blockade. The therapy signifi- cantly increased the median survival of mice (Fig. 7). Interestingly, the reduced growth of contralaterally injected B16F10 cells sug- gested the presence of a long lasting immunological memory also against non-targeted antigens. Concerning the functional state of tumor infiltrating lymphocytes (TILs), we found that all the immune therapies would enhance the percentage of activated (PD-1pos TIM- 3neg) T lymphocytes and reduce the amount of exhausted (PD-1pos TIM-3pos) cells compared to placebo. As expected, we found that PeptiCRAd monotherapy could increase the number of antigen spe- cific CD8+ T cells compared to other treatments. However, only the combination with PD-L1 blockade could significantly increase the ra- tio between activated and exhausted pentamer positive cells (p= 0.0058), suggesting that by disrupting the PD-1/PD-L1 axis we could decrease the amount of dysfunctional antigen specific T cells. We ob- served that the anatomical location deeply influenced the state of CD4+ and CD8+ T lymphocytes. In fact, TIM-3 expression was in- creased by 2 fold on TILs compared to splenic and lymphoid T cells. In the CD8+ compartment, the expression of PD-1 on the surface seemed to be restricted to the tumor micro-environment, while CD4 + T cells had a high expression of PD-1 also in lymphoid organs. Interestingly, we found that the levels of PD-1 were significantly higher on CD8+ T cells than on CD4+ T cells into the tumor micro- environment (p < 0.0001). Conclusions In conclusion, we demonstrated that the efficacy of immune check- point inhibitors might be strongly enhanced by their combination with cancer vaccines. PeptiCRAd was able to increase the number of antigen-specific T cells and PD-L1 blockade prevented their exhaus- tion, resulting in long-lasting immunological memory and increased median survival

AIDS Research and Human Retroviruses

Texto completo: acesso restrito. p. 365-371Human T-lymphotropic virus type I (HTLV-I) causes HTLV-I-associated myelopathy/tropical spastic paraparesis and adult T cell leukemia in a small percentage of infected individuals. HTLV-I infection is increasingly associated with clinical manifestations. To determine the prevalence of clinical manifestations in HTLV-I infected individuals, we conducted a cross-sectional study of 115 HTLV-I-infected blood donors without myelopathy and 115 age- and sex-matched seronegative controls. Subjects answered a standardized questionnaire and underwent physical examination. Compared with controls, HTLV-I-infected subjects were more likely to report arm or leg weakness (OR = 3.8, 95% CI: 1.4–10.2; OR = 4.0, 95% CI: 1.6–9.8, respectively), hand or foot numbness (OR = 2.1, 95% CI: 1.1–3.9; OR = 4.8, 95% CI: 2.0–11.7, respectively), arthralgia (OR = 3.3, 95% CI: 1.7–6.4), nocturia (OR = 2.7, 95% CI: 1.04–6.8), erectile dysfunction (OR = 4.0, 95% CI: 1.6–9.8), and to have gingivitis (OR = 3.8, 95% CI: 1.8–7.9), periodontitis (OR = 10.0, 95% CI: 2.3–42.8), and dry oral mucosa (OR = 7.5, 95% CI: 1.7–32.8). HTLV-I infection is associated with a variety of clinical manifestations, which may occur in patients who have not developed myelopathy

Antinociceptive activities of crude methanolic extract and phases, n-butanolic, chloroformic and ethyl acetate from Caulerpa racemosa (Caulerpaceae)

In this study, we attempted to identify the possible antinociceptive actions of n-butanolic phase, chloroformic phase, ethyl acetate phase and crude methanolic extract obtained from Caulerpa racemosa. This seaweed is cosmopolitan in world, mainly in tropical regions. The n-butanolic, chloroformic, ethyl acetate phases and crude methanolic extract, all administered orally in the concentration of 100 mg/kg, reduced the nociception produced by acetic acid by 47.39%, 70.51%, 76.11% and 72.24%, respectively. In the hotplate test the chloroformic and ethyl acetate phase were activite in this models. In the neurogenic phase on formalin test, were observed that crude methanolic extract (51.77%), n-butanolic phase (35.12%), chloroformic phase (32.70%) and indomethacin (32.06%) were effective in inhibit the nociceptive response. In the inflammatory phase, only the ethyl acetate phase (75.43%) and indomethacin (47.83%) inhibited significantly the nociceptive response. Based on these data, we can infer that the ethyl acetate phase shows a significant anti-inflammatory profile, whose power has not yet been determined. However, pharmacological and chemical studies are continuing in order to characterize the mechanism(s) responsible for the antinociceptive action and also to identify other active principles present in Caulerpa racemosa